

## Special Issue

# Antimicrobial Resistance: A Global Challenge

### Message from the Guest Editor

Antimicrobial resistance (AMR) has become a worldwide public health threat caused by inappropriate and massive consumption and disposal of antimicrobial drugs in the medicine, veterinary, zootechnical and agricultural fields. Infectious diseases can be caused by multidrug-resistant microorganisms (MDRO) in hospitals, communities and livestock, threatening medical procedures or food production chains of both animal and plant origin. As a global health challenge, an effective response to the AMR “silent pandemic” needs the One Health approach to reduce the risk for emerging zoonotic disease outbreaks as well as environmental spread of resistant pathogens and genes. This Special Issue will bring together scientific research studies and review papers focused on evidence-based interventions, sustainable use of antimicrobial treatments, monitoring strategies, tools, models, health determinants and estimates of the AMR burden in order to favor awareness and offer insights on how to address this critical issue for the ecosystem and human health.

---

### Guest Editor

Dr. Michela Sabbatucci

Department Infectious Diseases, Italian National Institute of Health, Rome, Italy

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/133054](https://mdpi.com/si/133054)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).